[1] KHAN S A,THOMAS H C,DAVIDSON B R,et al.Cholangiocarcinoma[J].Lancet,2005,366(9493):1303-1314.
[2] SHAIB Y H,DAVILA J A,MCGLYNN K,et al.Rising incidence of intrahepatic cholangiocarcinoma in the United States:a true increase？[J].J Hepatol,2004,40(3):472-477.
[3] ALVARO D,CROCETTI E,FERRETTI S,et al.Descriptive epidemiology of cholangiocarcinoma in Italy[J].Dig Liver Dis,2010,42(7):490-495.
[4] LEPAGE C,COTTET V,CHAUVENET M,et al.Trends in the incidence and management of biliary tract cancer:a French population-based study[J].J Hepatol,2011,54(2):306-310.
[5] PETROWSKY H,HONG J C.Current surgical management of hilar and intrahepatic cholangiocarcinoma:the role of resection and orthotopic liver transplantation[J].Transplant Proc,2009,41(10):4023-4035.
[6] JEMAL A,SIEGEL R,WARD E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-249.
[7] HEMMING A W,REED A I,FUJITA S,et al.Surgical management of hilar cholangiocarcinoma[J].Ann Surg,2005,241(5):693-699; discussion 699-702.
[8] SUNPAWERAVONG S,OVARTLARNPORN B,KHOW-EAN U,et al.Endoscopic stenting versus surgical bypass in advanced malignant distal bile duct obstruction:cost-effectiveness analysis[J].Asian J Surg,2005,28(4):262-265.
[9] ATIQ M,JAVLE M,DANG S,et al.Cholangiocarcinoma:an endoscopist's perspective[J].Expert Rev Gastroenterol Hepatol,2010,4(5):601-611.
[10] SEWNATH M E,KARSTEN T M,PRINS M H,et al.A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice[J].Ann Surg,2002,236(1):17-27.
[11] VANDER GAAG N A,RAUWS E A,van EIJCK C H,et al.Preoperative biliary drainage for cancer of the head of the pancreas[J].N Engl J Med,2010,362(2):129-137.
[12] SEILER C A,WAGNER M,SADOWSKI C,et al.Randomized prospective trial of pylorus-preserving vs.Classic duodenopancreatectomy (Whipple procedure):initial clinical results[J].J Gastrointest Surg,2000,4(5):443-452.
[13] SHIMODA M,KUBOTA K.Multi-disciplinary treatment for cholangiocellular carcinoma[J].World J Gastroenterol,2007,13(10):1500-1504.
[14] ALJIFFRY M,WALSH M J,MOLINARI M.Advances in diagnosis,treatment and palliation of cholangiocarcinoma:1990-2009[J].World J Gastroenterol,2009,15(34):4240-4262.
[15] NATHAN H,ALOIA T A,VAUTHEY J N,et al.A proposed staging system for intrahepatic cholangiocarcinoma[J].Ann Surg Oncol,2009,16(1):14-22.
[16] NAKAGAWA T,KAMIYAMA T,KURAUCHI N,et al.Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma[J].World J Surg,2005,29(6):728-733.
[17] SHIMADA K,SANO T,NARA S,et al.Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement[J].Surgery,2009,145(4):411-416.
[18] MEYER C G,PENN I,JAMES L.Liver transplantation for cholangiocarcinoma:results in 207 patients[J].Transplantation,2000,69(8):1633-1637.
[19] RAJAGOPALAN V,DAINES W P,GROSSBARD M L,et al.Gallbladder and biliary tract carcinoma:a comprehensive update,Part 1[J].Oncology (Williston Park),2004,18(7):889-896.
[20] DAINES W P,RAJAGOPALAN V,GROSSBARD M L,et al.Gallbladder and biliary tract carcinoma:a comprehensive update,Part 2[J].Oncology (Williston Park),2004,18(8):1049-1059; discussion 1060,1065-1066,1068.
[21] ANDERSON C,KIM R.Adjuvant therapy for resected extrahepatic cholangiocarcinoma:a review of the literature and future directions[J].Cancer Treat Rev,2009,35(4):322-327.
[22] CASSIER P A,THEVENET C,WALTER T,et al.Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma[J].Eur J Gastroenterol Hepatol,2010,22(9):1111-1117.
[23] VALLE J,WASAN H,PALMER D H,et al.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer[J].N Engl J Med,2010,362(14):1273-1281.
[24] SHARMA A,DWARY A D,MOHANTI B K,et al.Best supportive care compared with chemotherapy for unresectable gall bladder cancer:a randomized controlled study[J].J Clin Oncol,2010,28(30):4581-4586.
[25] LEE D K.Drug-eluting stent in malignant biliary obstruction[J].J Hepatobiliary Pancreat Surg,2009,16(5):628-632.
[26] HONG K,GESCHWIND J F.Locoregional intra-arterial therapies for unresectable intrahepatic cholangiocarcinoma[J].Semin Oncol,2010,37(2):110-117.
[27] TODOROKI T,OHARA K,KAWAMOTO T,et al.Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma[J].Int J Radiat Oncol Biol Phys,2000,46(3):581-587.
[28] ROY R,MARAVEYAS A.Chemoradiation in pancreatic adenocarcinoma:a literature review[J].Oncologist,2010,15(3):259-269.
[29] KOPEK N,HOLT M I,HANSEN A T,et al.Stereotactic body radiotherapy for unresectable cholangiocarcinoma[J].Radiother Oncol,2010,94(1):47-52.
[30] SHINOHARA E T,GUO M,MITRA N,et al.Brachytherapy in the treatment of cholangiocarcinoma[J].Int J Radiat Oncol Biol Phys,2010,78(3):722-728.
[31] COVEY A M,BROWN K T.Palliative percutaneous drainage in malignant biliary obstruction.Part 2:Mechanisms and postprocedure management[J].J Support Oncol,2006,4(7):329-335.
[32] SIMMONS D T,BARON T H,PETERSEN B T,et al.A novel endoscopic approach to brachytherapy in the management of Hilar cholangiocarcinoma[J].Am J Gastroenterol,2006,101(8):1792-1796.
[33] NAG S,DEHAAN M,SCRUGGS G,et al.Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy[J].Int J Radiat Oncol Biol Phys,2006,64(3):736-744.
[34] NAG S,DEHAAN M,SCRUGGS G,et al.Adjuvant concurrent chemoradiation therapy (CCRT) alone versus CCRT followed by adjuvant chemotherapy:which is better in patients with radically resected extrahepatic biliary tract cancer？a non-randomized,single center study[J].BMC Cancer,2009,9:345.
[35] MAKUUCHI M,SUGAWARA Y.Current status of liver transplantation for hepatocellular carcinoma from living donors[J].Hepatol Res,2007,37 (Suppl 2):S277-278.
[36] SUDAN D,DEROOVER A,CHINNAKOTLA S,et al.Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma[J].Am J Transplant,2002,2(8):774-779.
[37] SPEER A G,COTTON P B,RUSSELL R C,et al.Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice[J].Lancet,1987,2(8550):57-62.
[38] LARGHI A,TRINGALI A,LECCA P G,et al.Management of hilar biliary strictures[J].Am J Gastroenterol,2008,103(2):458-473.
[39] MOSS A C,MORRIS E,LEYDEN J,et al.Malignant distal biliary obstruction:a systematic review and meta-analysis of endoscopic and surgical bypass results[J].Cancer Treat Rev,2007,33(2):213-221.
[40] KULLMAN E.Covered versus uncovered self-expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction:results from a randomized,multicenter study[J].Gastrointest Endosc,2010,72(5):915-923.
[41] KULLMAN E,FROZANPOR F,SODERLUND C,et al.Paclitaxel-eluting covered metal stents versus covered metal stents for distal malignant biliary obstruction:a prospective comparative pilot study[J].Gastrointest Endosc,2011,73(4):727-733.
[42] JANG S I,KIM J H,YOU J W,et al.Efficacy of a metallic stent covered with a paclitaxel-incorporated membrane versus a covered metal stent for malignant biliary obstruction:a prospective comparative study[J].Dig Dis Sci,2013,58(3):865-871.
[43] SHINCHI H,TAKAO S,NISHIDA H,et al.Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma[J].J Surg Oncol,2000,75(2):89-94.
[44] VALEK V,KYSELA P,KALA Z,et al.Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma:a prospective randomised study[J].Eur J Radiol,2007,62(2):175-179.
[45] KHAN S A,DAVIDSON B R,GOLDIN R D,et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma:an update[J].Gut,2012,61(12):1657-1669.
[46] CHEN Y,WANG X L,YAN Z P,et al.The use of 125I seed strands for intraluminal brachytherapy of malignant obstructive jaundice[J].Cancer Biother Radiopharm,2012,27(5):317-323.
[47] ZHU H D,GUO J H,ZHU G Y,et al.A novel biliary stent loaded with 125I seeds in patients with malignant biliary obstruction:preliminary results versus a conventional biliary stent[J].J Hepatol,2012,56(5):1104-1111.
[48] ORTNER M A.Photodynamic therapy for cholangiocarcinoma:overview and new developments[J].Curr Opin Gastroenterol,2009,25(5):472-476.
[49] KIESSLICH T,WOLKERSDORFER G,NEUREITER D,et al.Photodynamic therapy for non-resectable perihilar cholangiocarcinoma[J].Photochem Photobiol Sci,2009,8(1): 23-30.
[50] ZOEPF T,JAKOBS R,ARNOLD J C,et al.Palliation of nonresectable bile duct cancer:improved survival after photodynamic therapy[J].Am J Gastroenterol,2005,100(11):2426-2430.
[51] WITZIGMANN H,BERR F,RINGEL U,et al.Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma:palliative photodynamic therapy plus stenting is comparable to r1/r2 resection[J].Ann Surg,2006,244(2):230-239.
[52] GATTO M,BRAGAZZI M C,SEMERARO R,et al.Cholangiocarcinoma:update and future perspectives[J].Dig Liver Dis,2010,42(4):253-260.
[53] GORES G J.Cholangiocarcinoma:current concepts and insights[J].Hepatology,2003,37(5):961-969.
[54] LIM K,HAN C,XU L,et al.Cyclooxygenase-2-derived prostaglandin E2 activates beta-catenin in human cholangiocarcinoma cells:evidence for inhibition of these signaling pathways by omega 3 polyunsaturated fatty acids[J].Cancer Res,2008,68(2):553-560.
[55] SIRICA A E.Cholangiocarcinoma:molecular targeting strategies for chemoprevention and therapy[J].Hepatology,2005,41(1):5-15. |
